Introduction to Oncology and Chemotherapy October 23-24, 2013 San Francisco, CA

Size: px

Start display at page:

Download "Introduction to Oncology and Chemotherapy October 23-24, 2013 San Francisco, CA"

Amy Dalton
5 years ago
Views:

1 1 PROGRAM OUTLINE: Introduction to Oncology and Chemotherapy October 23-24, 2013 San Francisco, CA Description: Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed with emphasis on mode of action, dose intensity and chemotherapy regimes. The range of side effects of cancer treatments will be studied in detail. Quality of life issues in terms of overall assessment and result interpretation will also be discussed. Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, ovarian and prostate cancer and melanoma. Each session will be presented by clinicians active in these areas and will focus on overall patient presentation and management and cancer diagnosis and staging. Following these sessions, our experts will lead delegates in interactive group discussions on the key issues relating to effective management of each tumor type. The limitations of cytotoxic drugs currently available are well known. With this in mind, the course includes in-depth discussion on new drug development and identification of new pharmacological targets of particular interest and value. Clinical trial design issues will also be included. Topics include: Cancer: terminology and classification Introduction to anti-cancer drugs and side effects New developments in cancer therapy Introduction to the major tumor types: breast, lung, melanoma, upper GI, colorectal, ovarian and prostate cancer Clinical trial issues in oncology Course Instructors: John Chan, MD John A. Kerner Distinguished Professorship in Gynecologic Oncology Director of Gynecologic Oncology UCSF Hellen Diller Family Comprhensive Cancer Center Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Chief of Medical Oncology Duke University Medical Center Adil Daud, MD Professor of Clinical Medicine Co-Director, Melanoma Program University of California, San Francisco Thierry M. Jahan, MD Assistant Professor of Medicine Bonnie J. & Anthony Addario Endowed Chair in Thoracic Oncology Director, Clinical Services, Division of Hematology/Oncology

2 UCSF Helen Diller Family Comprehensive Cancer Center 2 Michelle Melisko, MD Associate Clinical Professor Division of Hematology and Oncology UCSF Helen Diller Family Comprehensive Cancer Center Bert O Neil, MD Associate Professor Clinical Research UNC Lineberger Comprehensive Cancer Center Who Should Attend: Healthcare s courses are designed for both medical and non-medical staff within the pharmaceutical industry. This course is suitable for clinical research, medical information, regulatory affairs, biometrics and strategic marketing personnel. Administrative/Venue Details: The registration fee at CHI s VIP Discount Rate is $3,885 USD (regular rate $4,586 USD). You save 15% off your registration by registering through Cambridge Healthtech Institute (CHI). This includes lunch and refreshments throughout the day. Accommodation costs are not included. Delegates can register on-line or by completing the booking form and returning it together with the appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your records. Venue TBA. The course will take place at a hotel close to the San Francisco airport. Full joining instructions will be supplied to registered delegates near the date of the course. Schedule: October 23: October 24: 8:15 am 5:15 pm 8:15 am 4:00 pm Course Schedule DAY 1 Wednesday, October 23: 8:15 am 5:15 pm 8:15 am Registration Tea/coffee on arrival 8:30 Welcome/Opening Remarks 8:35 Introduction to Cancer Clarification of terminology Classification of tumor types Principles of treatment and review of treatment options - chemotherapy - radiotherapy - surgical intervention Adjuvant and neoadjuvant therapy Endpoint assessment (rsponse/survival) Hematological malignancies 9:45 Discussion 10:00 Tea/coffee 10:20 Introduction to Anti-Cancer Drugs and Side Effects Classification of anti-cancer drugs Mechanisms of action Mono vs. combination therapy Chemotherapy regimes Dose intensity 11:20 Discussion

3 3 11:30 Clinical Trials - Overview 12:30 Lunch 1:30 Prostate Cancer Patient presentation Diagnosis and management Treatment of localized disease Treatment of advanced disease locally and metastatic 2:30 Prostate Cancer Case Presentations and Discussion 3:00 Tea/coffee 3:20 Breast Cancer Diagnosis and staging Review of surgical procedures Chemotherapeutic options Role of hormonal therapy 4:45 Breast Cancer Case Presentations and Discussion 5:15 Close of Day One DAY 2 Thursday, October 24: 8:15 am 4:00 pm 8:15 am Registration Continental breakfast available 8:30 Colorectal Cancer Patterns of presentation Diagnosis and management Surgery Chemotherapy Other treatment options 9:30 Colorectal Case Presentations and Discussion 9:45 Tea/coffee 10:00 Upper Gastrointestinal (GI) Cancer (esophagus, stomach, pancreas) Patterns of presentation Diagnosis and management Surgery Chemotherapy Radiotherapy 11:00 GI Case Presentations and Discussion 11:15 Ovarian Cancer Diagnosis and staging Review of surgical procedures Chemotherapeutic options Role of hormonal therapy

4 4 12:00 Ovarian Cancer Case Presentations and Discussion 12:15 Lunch 1:00 Lung Cancer Small cell vs. non small cell cancer Patient presentation Treatment options - surgery - chemotherapy - radiotherapy 2:00 Lung Cancer Case Presentations and Discussion 2:15 Tea/coffee 2:30 Melanoma Classification Diagnosis, staging and prognosis Current treatment options, their strengths and limitations 3:15 Melanoma Case Presentations and Discussion 3:45 Summary/Closing Remarks 4:00 Close

5 5 About our Course Instructors John K. Chan MD Dr. John K. Chan is the Director of the Division of Gynecologic Oncology and Associate Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco. He currently holds the John A. Kerner Distinguished Professorship in Gynecologic Oncology. Dr. Chan received his Medical Degree from the University of California, Los Angeles, followed by Residency in Obstetrics and Gynecology at the University of California, Irvine and Fellowship in Gynecologic Oncology at the University of California, Irvine and the MD Anderson Cancer Center. His research focuses on developing new therapies for gynecologic cancers, including genomic therapy and targeted biologic therapies, as well as investigating the role of tumor initiating cells in ovarian cancer. He is involved in outcomes-based studies examining the treatment and outcomes of ovarian and uterine cancer patients. Dr. Chan has also recently been appointed as the principal investigator for one of the largest advanced ovarian cancer clinical trials in the country, which is currently open through the Gynecologic Oncology Group. He has received research funding from the National Institutes of Health and the Institute of Aging to study the effects of prophylactic surgery on ovarian cancer risk. Dr. Chan is an active member of the Gynecologic Oncology Group Ovarian Cancer Committee and is serving as the study chair for three Gynecologic Oncology Group protocols. He has received numerous grants and awards, including those from the National Cancer Institute, the Ovarian Cancer Research Foundation, and the Gynecologic Oncology Group. Dr. Chan was selected as a member of the Scientific Program Committee for the Society of Gynecologic Oncologists and has played a major role in organizing educational programs for national and international gynecologic cancer societies. He is an active member in numerous academic organizations including the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists. Dr. Chan has authored and co-authored nearly 100 manuscripts in journals including Gynecologic Oncology, Cancer, Obstetrics & Gynecology, Journal of Clinical Oncology, British Journal of Cancer, American Journal of Obstetrics and Gynecology, Lancet Oncology, Cancer Research, and Clinical Cancer Research. He is also the co-author of three textbooks in the field of Gynecologic Oncology. Jeffrey Crawford, MD Jeffrey Crawford is the George Barth Professor for Research in Cancer and Chief of Medical Oncology in the Department of Medicine at the Duke University Medical Center. Dr. Crawford earned his medical degree at Ohio State University, USA. He was an Intern, Junior and Senior Assistant Resident in Medicine, and a Hematology/Oncology fellow at Duke University. Dr. Crawford later became Chief Resident in Medicine at Duke University/Veteran s Administration Medical Center, and also a Geriatric Fellow. He is board certified in Internal Medicine as well as in the Hematology and Oncology subspecialties. Dr. Crawford s research interests include new treatment approaches in lung cancer, supportive cancer therapies and clinical trials of hematopoietic growth factors, biological agents and targeted drug development. He has led many US trial investigations on various cancer drugs, several of which have resulted in FDA approval. He also holds several positions with the National Comprehensive Cancer Network (NCCN), including chair of the Myeloid Growth Factor Committee and member of the Clinical Trials Network Investigator Steering Committee. Dr. Crawford is vice-chair of the respiratory committee of the Cancer and Leukemia Group B (CALGB) and is Principal Investigator in the CALGB for Duke. Dr. Crawford is the Principal Investigator for the Cancer Biology and Research T32 training grant at Duke. He has served multiple leadership roles in the American Society of Clinical Oncology (ASCO), the Multinational Association of Supportive Care (MASCC), Advisor of the Chinese Geriatric Oncology Society and is a member of the Curriculum Planning Executive Committee of the International Association for Study of Lung Cancer (IASLC). He is a steering committee member of the Awareness of Neutropenia in Chemotherapy (ANC) Study Group. This group has been instrumental in the development and analysis of the largest prospective study of chemotherapy delivery in the United States. Dr. Crawford has authored or co-authored 145 scientific articles, 60 book chapters and reviews, 180 abstracts and is co-editor of the book Cancer Supportive Care. He serves on the editorial boards of several journals. Dr. Crawford has received the Outstanding Service

6 6 Award, Cancer Care, Inc, NY, America s Top Doctors Award, Castle Connolly Medical Ltd, the Wayne Rundles Award for Excellence in Clinical Research, the Joseph Greenfield Research Faculty Award and the Wendell Rosse Teaching Award. Adil Daud, MD Dr. Adil Daud is Associate Professor of Clinical Medicine at the University of California, San Francisco where he leads the Melanoma Clinical Research team. He completed his Hematology/Oncology fellowship in 2000 at Memorial Sloan Kettering Cancer Center in New York where he stayed as a Clinical Attending before moving to University of South Florida as an Assistant Professor in In 2006, Dr. Daud became the Director of the Moffit Affiliate Research Network (currently this network has 16 hospitals-medical centers with 200 physicians in the state of Florida). Dr. Daud became Associate Professor of Clinical Medicine in 2008 and leads a dynamic team at the University of California San Francisco. His interests are in developing novel treatments for melanoma and after skin cancer. Thierry Jahan, MD Dr Thierry Jahan is one of the region's foremost and highly regarded thoracic oncologists. Dr. Jahan has devoted his life to treating patients with lung cancer, mesothelioma and sarcoma. Dr. Jahan received his M.D. from George Washington University. He completed his residency and an internal medicine fellowship at Cedars Sinai Medical Center in Los Angeles, followed by a fellowship in hematology and oncology at UCSF. In 1994, Dr. Jahan joined the UCSF faculty and later, with Dr. David M. Jablons, cofounded the Thoracic Oncology Program. Dr. Jahan currently holds the title of Associate Professor of Medicine at the UCSF School of Medicine. Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists. Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. The San Francisco Chronicle, Time Magazine and KPIX in San Francisco have each sought out his insights and observations on the clinical and human side of battling serious life-threatening cancers. Dr. Jahan is Principal Investigator on numerous thoracic oncology clinical trials. He has a particular interest in testing target therapies in non-small cell lung cancer malignant mesothelioma as either single agents or in combination with chemotherapy and/or radiation. Michelle E. Melisko, MD Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain. She also hopes to educate patients and encourage their participation in clinical trials to make more rapid advances in breast cancer treatment. Melisko earned a medical degree at the Wake Forest University School of Medicine and completed a residency in internal medicine at Stanford Hospital and Clinics and a fellowship in hematology and oncology at UCSF Medical Center. Bert H. O Neil, MD Bert H. O Neil, MD, is an Associate Professor in the Division of Hematology and Oncology at the University of North Carolina at Chapel Hill. Dr. O Neil earned his BS in biology at the University of California at Irvine and his MD at the UCLA School of Medicine. After graduating, he completed his residency in internal medicine at the University of California at San Francisco. His fellowship in hematology and oncology was also conducted at the University of California at San Francisco. Currently, Dr. O Neil serves as the Medical Director of the UNC Cancer Clinical Trials Protocol Office, Director of the Gastrointestinal Cancer Research Program at UNC, and the Section Chief of GI malignancies at UNC. He is also a Cadre Member of the CALGB GI Committee and a CALGB Study Chair. Dr. O Neil s research interests include elucidation of novel mechanisms of resistance to radiation therapy in rectal cancer, and early drug development for gastrointestinal malignancies, particularly colorectal cancer and hepatocellular carcinoma. Charles J. Ryan, MD Dr Charles J. Ryan is a medical oncologist specializing in the treatment of thoracic and urologic malignancies. As a physician In the Thoracic Oncology Program, Dr. Ryan treats patients with non-small cell lung cancer, small cell lung cancer, BAC, mediastinal tumors and pulmonary metastases. Dr. Ryan is a member of the UCSF Helen Diller Family Comprehensive Cancer Center where he conducts research investigating the most promising targeted

7 7 therapies and novel agents for the treatment of cancer. Dr. Ryan has served as a Principal Investigator on a number of clinical trials and has authored numerous articles on molecularly targeted therapies. Dr. Ryan earned his medical degree at the University of Wisconsin School of Medicine, where he also completed a residency in internal medicine. He then was accepted into a prestigious clinical fellowship program at Memorial Sloan-Kettering Cancer Center (MSKCC) where he received advanced state-of-the-art training in medical oncology. At MSKCC, Dr. Ryan took care of patients with complex and challenging cancers, many of whom had been diagnosed with advanced lung cancer.

8 8 Course Registration Form Introduction to Oncology and Chemotherapy October 23-24, San Francisco, CA Venue TBA Fill out and fax back to James Prudhomme at If you are paying by check or have any questions regarding payment, please call To inquire about a group discount, call Fee: VIP Discount Rate $3,885 USD (regular rate $4,586 USD) YOUR DETAILS: Title: (tick applicable) Dr. Mr. Mrs. Ms. Miss Other First Name Last Name Company Job Title Department Address City State Country Telephone Fax Charge my credit card VISA MasterCard American Express Maestro* *Only debit cards issued by a UK bank can be accepted. Name (as it appears on card) Account Number Start Date (mm/yy) End Date (mm/yy) Security Number (from rear/front of card) Signature Please note: No refund/credit of registration fee will be made for any cancellations received less than 20 working days prior to the date of the course. Cancellations made more than 20 working days prior to course date will incur a $175 (USD) administration fee. Substitutions may be made at any time. If Healthcare cancels or postpones this event, the registration fee will be refunded. Healthcare will not accept liability for any other costs. Healthcare reserves the right to amend the content and timing of all courses. Your details will be entered onto our database and we may, from time to time, advise you of other products that may be of interest to you. If you do not wish to receive this information then please let us know.

Introduction to Oncology: Focus on Solid Tumors October 22-23, 2014 San Francisco, CA

Introduction to Oncology: Focus on Solid Tumors October 22-23, 2014 San Francisco, CA www.healthtech.com/ioc Description: Delegates attending this course will benefit from an introductory overview of the